Stromal-driven and Amyloid β-dependent induction of neutrophil extracellular traps modulates tumor growth. by Munir, Hafsa et al.
ARTICLE
Stromal-driven and Amyloid β-dependent induction
of neutrophil extracellular traps modulates tumor
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Tumors consist of cancer cells and a network of non-cancerous stroma. Cancer-associated
fibroblasts (CAF) are known to support tumorigenesis, and are emerging as immune mod-
ulators. Neutrophils release histone-bound nuclear DNA and cytotoxic granules as extra-
cellular traps (NET). Here we show that CAFs induce NET formation within the tumor and
systemically in the blood and bone marrow. These tumor-induced NETs (t-NETs) are driven
by a ROS-mediated pathway dependent on CAF-derived Amyloid β, a peptide implicated in
both neurodegenerative and inflammatory disorders. Inhibition of NETosis in murine tumors
skews neutrophils to an anti-tumor phenotype, preventing tumor growth; reciprocally, t-NETs
enhance CAF activation. Mirroring observations in mice, CAFs are detected juxtaposed to
NETs in human melanoma and pancreatic adenocarcinoma, and show elevated amyloid and
β-Secretase expression which correlates with poor prognosis. In summary, we report that
CAFs drive NETosis to support cancer progression, identifying Amyloid β as the protagonist
and potential therapeutic target.
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The tumor microenvironment comprises a complex niche ofcancer cells and “normal” cell populations collectivelyreferred to as the stroma. The stroma includes leukocytes,
cancer-associated fibroblasts (CAFs), pericytes, blood vessels and
lymphatic vessels1. Tumor development is accompanied by
changes in the phenotype, function and interactions between
these stromal constituents2–5, a process which is central to
carcinogenesis.
CAFs are one of the most abundant stromal populations in the
tumor, and display considerable heterogeneity and plasticity6.
Multiple tumor-promoting functions have been attributed to
CAFs, including promoting angiogenesis, remodeling extra-
cellular matrix7,8, modifying tumor stiffness9,10, nutrient pro-
cessing11, and facilitating the invasion of tumor cells1,4. More
recently, CAFs have emerged as modulators of the innate and
adaptive immune responses as they are recruited to the tumor.
CAF-derived factors have been shown to drive the recruitment
and M2 polarization of macrophages12. CAFs drive T-cell dele-
tion and exhaustion in an antigen-dependent manner by FASL
and PD-L2 mediated interactions5. CAFs also mediate exclusion
of T-cells from tumors via the production of CXCL122. Fur-
thermore, CAF-derived IL-6 can induce systemic immunosup-
pressive effects13. Collectively, these data demonstrate that anti-
cancer immune responses can be modulated by CAFs, and failure
of the immune system to control cancer is not solely mediated by
cancer cells but also the surrounding stroma.
Neutrophils are the most abundant circulating leukocyte
population, functioning as early responders to inflammatory
insult14. Following activation, neutrophils utilize several
mechanisms to exert their effects, such as secreting inflammatory
factors that influence other immune populations, production of
reactive oxygen species (ROS) and cytotoxic granular proteins to
eliminate pathogens, as well as releasing extracellular traps
(NETs). NETs are composed of chromatin-bound DNA, deco-
rated in cytosolic and granular proteins such as myeloperoxidase
(MPO) and neutrophil elastase (NE)14. Though the molecular
mechanisms governing NET release are still not completely
understood, in certain contexts it requires ROS-mediated, cal-
cium driven citrullination of histones by Protein Arginine Dei-
minase 4 (PAD4)14.
NETs detected in chronic inflammatory disorders exert their
pro-inflammatory effects by modulating the activity of other
stromal populations at the site of tissue damage. In murine
models of inflammation, such as systemic lupus erythematosus,
NETs activate plasmacytoid dendritic cells through engagement
of TLR9, thus exacerbating the condition15,16. In addition, NETs
have been shown to reduce the threshold for the activation of
CD4+ T-cells in response to antigen17. As well as regulating
immune cells, NET-derived components were found to induce
activation of lung fibroblasts in a lung fibrosis model, promoting
their differentiation into myofibroblasts18. Subsequent collagen
deposition, proliferation and migration of the differentiated
myofibroblasts was also enhanced by treatment with NETs18.
While the roles of neutrophils in infection have been well
established, their contribution to tumor progression, immune
evasion and metastasis remain controversial. Indeed, neutrophils
have been reported to exert both anti- and pro-tumorigenic
effects depending on the environmental cues to which they are
exposed19,20. This plasticity has made it difficult to ascertain the
spatial and temporal nature of neutrophil functions within
tumors. NETs have been identified as modulators of cancer-
induced thrombosis through a granulocyte-colony-stimulating
factor (G-CSF) dependent mechanism21 and facilitate metastasis
by capturing circulating tumor cells to promote colonization of
distal sites22–25. They have also been detected in several blood
cancers26–28 and recently, NET-mediated remodeling of the
extracellular matrix has been reported to awaken dormant cancer
cells and promote aggressive lung metastasis29. While observed in
primary tumors, the contribution of NETs to tumorigenesis and
underlying mechanisms are lacking22,30–34.
Here, we explore the interactions between CAFs and tumor-
infiltrating neutrophils in three different models of cancer,
determining the effects of CAF-derived factors on the capacity of
neutrophils to undergo NETosis and how this process influences
tumor growth. We show that CAF-secreted Amyloid β drives
formation of tumor-associated NETs (t-NETs) through CD11b in
a ROS-dependent mechanism both within the microenvironment
and at systemic levels in the blood and bone marrow. Therapeutic
inhibition of t-NETosis, or prevention of Amyloid β release by
CAFs abolishes growth of established tumors and restores an
anti-tumor status in the tumor-infiltrating neutrophils, indicating
a potential axis to be exploited therapeutically in multiple
cancer types.
Results
While neutrophils are observed in tumors, little is known about
how micro-niches created by stromal compartments perturb the
activity of these immune cells. In primary murine pancreatic and
skin (melanoma) tumors we observed that neutrophils were fre-
quently confined to CAF-rich regions (Fig. 1A) implying a
potential for cross-talk between the two populations.
Influence of CAF-derived factors on neutrophil function. To
determine if CAF-derived factors have the capacity to impact
aspects of neutrophil behavior, we first treated bone marrow-
derived neutrophils with conditioned media (CMed) from CAFs,
tissue-matched normal FBs, or Phorbol 12-myristate 13-acetate
(PMA; a well-known activator of neutrophils) and assessed via-
bility, surface activation markers, ROS production and phagocytic
capability of the neutrophils. Isolated CAFs were characterised
based on surface expression of classic markers; Thy1, Podoplanin
and PDGFRα (Supplementary Fig. 1A) and lack of immune
(CD45) and epithelial (EpCAM) markers (Supplementary
Fig. 1A). Lung and pancreatic FB or CAF CMed had no impact
on neutrophil viability for the duration of treatment while PMA
induced low levels of neutrophil death (Supplementary Fig. 1B).
Expression of activation markers (CD11b and CD18) tended to
increase in response to lung CAF CMed treatment (Supplemen-
tary Fig. 1C) in the presence or absence of an additional
inflammatory insult (Lipopolysaccharide; LPS). CAF CMed failed
to induce ROS production in neutrophils (Supplementary
Fig. 1D) nor did the cells exhibit enhanced phagocytic capabilities
(Supplementary Fig. 1E) relative to PMA after 30 min treatment.
Therefore, the classical functions of neutrophils14 were largely
unaltered by treatment with CAF-derived factors in vitro.
CAF-derived factors induce NETs in primary tumors. Having
already observed neutrophils in proximity to CAF-rich regions,
we also detected the presence of NETs within primary murine
pancreatic, skin and lung tumors (Fig. 1B and Supplementary
Fig. 1F). NETs were defined as staining positive for extracellular
DNA, MPO and Citrullinated histone H3 (CitH3). We termed
these structures tumor-induced NETs (t-NETs), and thus sought
to examine the role of t-NETs in the primary tumor, focusing on
the mechanisms driving their release.
To determine if CAF-derived factors drive the generation of t-
NETs, we treated isolated bone marrow neutrophils with CAF or
FB CMed and analyzed NETosis (Supplementary Fig. 2A, B and
Supplementary Movie 1). While CMed from normal FBs was
unable to induce NETs, CAF CMed from pancreatic, lung and
skin tumors was sufficient to induce NETosis to levels comparable
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with PMA (Fig. 1C and Supplementary Fig. 2B). As NETosis is
thought to be largely a “suicidal” process14, we next quantified
neutrophil death following longer-term exposure to CAF CMed
(compared to 30min treatment in Supplementary Fig. 1B). After
3 h of treatment with CAF CMed, a trend of increasing cell death
was observed compared to untreated neutrophils and to levels
comparable with PMA (Fig. 1D). This was confirmed by staining
of NETting neutrophils with live/dead dye (Fig. 1E) indicating that
CAF-influenced NETosis is a cell-death dependent effect. As
autophagy has also been implicated as a mode of death in
NETosis34, we then quantified the level of NETosis in the presence
of chloroquine, an inhibitor of autophagy. Chloroquine did not
rescue the neutrophils from undergoing NETosis (Supplementary
Fig. 2C) ruling out autophagy as a mechanism underlying CAF-
induced t-NET formation.
G-CSF and intracellular ROS have been reported to induce
citrullination of Histone H3 which is required for NET
formation35. Thus, to determine if CAF-derived factors stimulate
t-NETs in a ROS-dependent manner, we first inhibited ROS
production. Pre-treatment of neutrophils with N-acetylcysteine
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(NAC; Fig. 1F) Diphenyleneiodonium (DPI), Trolox or Vitamin
C (Supplementary Fig. 2D–F) prior to CAF CMed treatment
suppressed NET formation, indicating that ROS production by
neutrophils in response to CAF-derived factors is a key mediator
in the process. However, unlike previous reports which showed
that tumor-derived G-CSF drives NETosis systemically, here
CAF-mediated NETosis was not driven by G-CSF as NET release
was not significantly reduced following neutralization of G-CSF
in vitro (Fig. 1G). Together, these data suggest that CAFs are key
drivers of ROS-dependent, suicidal t-NETosis and the potential
factors that induce t-NETs in this context are likely distinct from
those previously reported21,34.
CAF-derived factors induce systemic effects on neutrophils. We
next investigated whether CAF-derived factors could render cir-
culating neutrophils more susceptible to NETosis before being
recruited into the tumor. Indeed, we observed that bone marrow-
derived neutrophils isolated from pancreatic, lung and skin
tumor-bearing mice displayed a greater propensity to generate t-
NETs in the absence of an additional stimulus compared to
neutrophils from non-tumor-bearing mice (Fig. 2A). With pan-
creatic tumors, but not for either lung or skin, this was accom-
panied by an increase in neutrophil death in the bone marrow
(Supplementary Fig. 3A). However, there was not a significant
increase in the number of neutrophils isolated from tumor-
bearing mice (Fig. 2B).
To determine whether CAF-derived factors were sufficient to
drive the observed susceptibility of bone marrow-derived
neutrophils towards NETosis, we intravenously (I/V) infused
CMed from pancreatic or lung-derived FBs or CAFs in the
absence of tumors. Spontaneous NET production by bone
marrow-derived neutrophils ex vivo was significantly enhanced
in wild-type mice treated with CAF CMed compared to FB CMed
or basal media (Fig. 2C) with concurrent increases in neutrophil
death (Supplementary Fig. 3B) and counts (Fig. 2D). The
increases in neutrophil number observed following CAF and FB
CMed infusion indicates that FB and CAFs may also be a source
of additional factors, such as G-CSF capable of boosting
neutrophil production. Discrepancies between neutrophil counts
after I/V infusion of the CMed vs. tumor- bearing mice may
reflect a difference in the concentration of factors capable of
driving neutrophil expansion in CMed infused compared to the
amount secreted by the tumor stroma.
CAF-driven t-NETs are pro-tumorigenic. Having shown that
CAFs can promote t-NETosis at local and systemic levels we next
sought to determine the functional impact of the t-NETs on
primary tumor development. Previous studies have analyzed the
effect of neutrophil depletion on tumor progression, primarily by
using anti-Ly6G antibodies36–38, however when studying NETo-
sis this approach would have confounding effects as a result of
their depletion. Therefore, to disrupt NETosis without impacting
other neutrophil functions, we inhibited PAD4 which drives
citrullination of histones to facilitate DNA release14. To first
ascertain the requirement of PAD4 in CAF-driven NETosis, we
tested the effects of its inhibition on neutrophils in vitro. A
complete suppression of CAF CMed-induced NET release was
observed in neutrophils treated with the PAD4 inhibitor, Cl-
amidine, in vitro (Fig. 2E). Moreover, treatment with Cl-amidine
in vivo prior to I/V infusion of lung CAF CMed was sufficient to
abolish NET release by bone marrow-derived neutrophils along
with a reduction in neutrophil death ex vivo (Fig. 2F and Sup-
plementary Fig. 3C). The number of bone marrow neutrophils
was largely unaffected (Fig. 2G) suggesting that NETosis was
inhibited without influencing other factors driving an increase in
neutrophil number.
In vivo, we focused on the effect of blocking t-NETs on the
development of primary skin and pancreatic tumors. Lung
adenocarcinomas were not examined following observations
that they only developed a significant CAF compartment when
the tumors were higher grade, thus confounding our ability to
determine the importance of CAF-driven NETosis on tumor
progression. Mice bearing established melanoma were treated
with GSK484, Cl-amidine (PAD4 inhibitors) or DMSO for
7 days (Fig. 3A and Supplementary Fig 4A). Cl-amidine
treatment completely inhibited tumor growth compared with
vehicle controls (Supplementary Fig 4A). This stasis effect was
replicated following treatment with the more specific PAD4
inhibitor, GSK484 (Fig. 3B). While tumor volumes were
drastically different following inhibition of t-NETosis, we did
not observe a significant effect on tumor immune infiltrates
and resident stroma by flow cytometry profiling (Fig. 3C and
Supplementary Fig. 4B, C, E). Importantly, the number of
neutrophils recruited to tumors was unaffected by PAD4
inhibition, indicating that treatment effects on neutrophil
behavior were specific to NETosis at the tumor (Fig. 3C, D and
Supplementary Fig. 4B). Suppression of tumor growth was not
due to direct toxicity of the small molecule inhibitors on
cancer cells. Indeed, treatment with GSK484, had no effect
on the growth of melanoma cells in vitro (Supplementary
Fig. 4F), while treatment with Cl-amidine only mildly affected
cell growth (non-significant; Supplementary Fig. 4F) which
could be a potential consequence of the broader action of
Cl-amidine.
With the knowledge that circulating NETs have been reported
to contribute to thrombus formation in advanced disease, we also
examined the plasma of mice treated with PAD4 inhibitors.
GSK484, but not Cl-amidine treatment was accompanied by
lower levels of the clotting factors von willebrand factor (vWF),
Fig. 1 CAF-derived factors induce NETosis in vitro and in vivo. A Confocal microscopy of myeloperoxidase (MPO) and podoplanin (PDPN) expressed on
neutrophils and CAFs respectively in pancreatic, skin tumors. B Confocal microscopy of NETs in murine pancreatic, skin tumors showing expression of
myeloperoxidase (MPO) and Citrullinated histone H3 (CitH3) by NETting neutrophils and podoplanin (PDPN) by CAFs. C Quantification of the area of the
field covered by SYTOX green positive neutrophil-derived extracellular DNA relative to the number of neutrophils in each field after treatment with
pancreatic, lung or skin FBs CMed, CAF CMed or PMA for 3 h. D The percentage of dead neutrophils after treatment with pancreatic, lung or skin CAF
CMed or PMA based on the number of SYTOX green positive neutrophils. E Confocal microscopy of bone marrow neutrophils stained with MPO, CitH3
and live/dead cell viability dye after induction of NETosis by treatment with CAF CMed for 3 h. Quantification of the relative NET coverage of neutrophils
treated with CAF CMed with or without pre-treatment with F N-acetyl-cysteine (NAC) or G anti-granulocyte colony-stimulating factor (α-GCSF). Data are
mean ± SEM; *p < 0.05, **p < 0.01 and ***p < 0.001 using (C, F and G) one-way ANOVA with a Tukey post hoc test (with the exception of 1C, untreated vs
PMA, which was performed with a paired t-test) and (D) paired t-test. Assays were performed on (A–B) Representative images of n= 6 tumors, (C) n= 7,
4 and 7 (Pancreatic for unstimulated, FB CMed and CAF CMed treated, respectively), n= 11, 3 and 10 (Lung for unstimulated, FB CMed and CAF CMed
treated, respectively), n= 4, 4 and 6 (Skin for unstimulated, FB CMed and CAF CMed treated, respectively) and n= 9 (PMA), (D) n= 4, (E) n= 2, F n= 4
(Pancreatic and Skin) n= 5 (Lung) and (G) n= 4 independent experiments. Scale bars are 50 µm.
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while the levels of fibrinogen were unchanged (Fig. 3E and
Supplementary Fig. 4D) suggestive of a reduction in NET-
mediated thrombosis within the circulation of treated mice.
Since the anti-tumor effects of t-NET inhibition were not
directed by secondary effects on other infiltrating immune
populations, we then examined the neutrophils themselves in
more detail. Following treatment with CAF CMed and PAD4
inhibitor for 3 h in vitro to prevent NETs, neutrophils increased
expression of activation markers CD11b and CD18, and
completely shed surface CD62L (Fig. 3F), typical of activated
neutrophils. Phagocytosis was reduced and intracellular ROS
levels were exhausted, consistent with depletion following an
oxidative burst (Fig. 3G, H). Furthermore, neutrophils exhibited
enhanced degranulation with increasing expression of surface
CD35 and CD63 after PAD4 inhibition that is associated with a
pro-inflammatory phenotype (Fig. 3I). To test the pro-inflamma-
tory, anti-tumor potential of degranulation following PAD4
inhibition, tumor cells were incubated in media from control or
PAD4 inhibitor treated neutrophils that had been stimulated with
CAF CMed. Media components from PAD4-inhibited neutrophils
significantly impaired tumor cell growth compared to control
conditions (Fig. 3J). Together these data support the concept that
t-NETs are pro-tumorigenic, and their inhibition is sufficient to
prevent growth of established tumors through the restoration of
an inflammatory state in tumor-infiltrating neutrophils.
The success of PAD4 inhibition in melanoma was not
recapitulated in the KPC genetic model of pancreatic cancer,
with no significant difference in tumor size being observed after
treatment (Supplementary Fig. 5A, B). Nonetheless, systemic
effects were detected, with PAD4 inhibition reducing levels of
clotting factors in the plasma (Supplementary Fig. 5C) as with
melanoma. Similarly, no significant changes in the stromal
landscape within the tumor were detected (Supplementary
Fig. 5D, E). While the treatment was effective systemically, as
evidenced by reduced clotting, we suggest that the lack of impact
on these tumors, which still contained t-NETs (Fig. 1B), may be
due to a lack of drug penetration which is a well-known
phenomenon in mouse and human pancreatic cancer39,40.
Indeed, supporting this, treatment of syngeneic pancreatic tumors
(induced by injecting KPC-derived cells into wild-type mice;
Supplementary Fig. 6A) with GSK484 completely suppressed
tumor growth compared with vehicle-treated mice (Supplemen-
tary Fig. 6B) mirroring the effects seen in melanoma. Here, we
observed that neutrophils and NETs (Supplementary Fig. 6C, D,
respectively) were frequently confined to CAF-rich regions of
vehicle-treated pancreatic tumors. As with melanoma, treatment
Fig. 2 CAF-derived factors drive NETosis systemically. Quantification of A relative NET coverage and B relative number of bone marrow neutrophils
taken from mice with pancreatic, lung or skin tumors. Quantification of the C relative NET coverage and D relative number of bone marrow neutrophils
isolated from wild-type mice intravenously infused with pancreatic or lung FB or CAF CMed 24 h before analysing NETosis. E Quantification of relative NET
coverage after stimulation with pancreatic CAF CMed with or without treatment with Cl-amidine in vitro. F Quantification of the relative NET coverage
and G relative number of bone marrow neutrophils isolated from mice intravenously infused with lung CAF CMed with or without pre-treatment with
Cl-amidine for 24 h. Data are mean ± SEM; *p < 0.05, **p < 0.01 and ***p < 0.001 using (A and F) paired t-test and C–E one-way ANOVA with a Dunnett
post hoc test. Assays were performed on A–B n= 4 (in duplicate), n= 7 (in quadruplet) and n= 7 for pancreatic, lung and skin tumor-bearing mice
respectively, C–D n= 8, 4 and 8 (Pancreatic for basal media, FB CMed and CAF CMed treatment, respectively. All performed in triplicate) and n= 9, 6 and
9 (Lung for basal media, FB CMed and CAF CMed treated, respectively. Performed in duplicate for basal media and CAF CMed and only a single time for FB
CMed treated), E n= 3 (in triplicate) and F–G n= 8 (in triplicate) independent experiments.
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with GSK484 did not affect neutrophil infiltration into the tumor
but NETs were absent (Supplementary Fig. 6C, D). Furthermore,
GSK484 treatment suppressed the capacity of bone marrow
neutrophils in tumor-bearing mice to NET, which coincided with
a reduction in neutrophil death without affecting the number of
neutrophils within the bone marrow (Supplementary Fig. 6E).
Moreover, in PAD4−/− mice, where neutrophils are genetically
incapable of undergoing NETosis, induced pancreatic tumors
grew significantly slower than those generated in wild-type
littermates (Supplementary Fig. 6F), echoing the effects of
pharmacologic NET inhibition. Thus, in multiple model systems,
inhibiting PAD4 and prevention of NETosis exerted a significant
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effect on tumor growth. Collectively, these data indicate that t-
NETs play a critical role in tumor progression.
CAF-derived Amyloid β drives t-NET formation. As neu-
trophils within the tumor traverse CAFs before entering the main
tumor bulk, we next assessed whether direct contact was required
for NET generation, or whether it was entirely soluble-mediator
dependent as we observed systemically. To evaluate the capacity
of CAFs to induce NETs by direct cell-cell interaction vs. secreted
factors, neutrophils were seeded onto pancreatic tumor-derived
CAFs in the presence or absence of FB or CAF CMed. While
CAFs in the presence of CAF CMed readily induced NETosis,
CAFs with normal media or FB CMed could not (Fig. 4A). This
suggested that direct contact between CAFs and neutrophils was
not sufficient to drive t-NETosis, and the effect is primarily
mediated through factors secreted by the CAFs. We established
that the CAF-derived factor was not vesicle bound as depletion of
microvesicles in the CMed had no effect on CAF CMed driven
NETosis (Fig. 4B), and media fractionation further confirmed
that the soluble mediator driving NETosis was a protein and not a
metabolite (Fig. 4C).
Therefore, we performed proteomic analysis of the pancreatic
FB and CAF CMed to identify the potential t-NET driver(s). Mass
spectrometry revealed a number of differentially secreted proteins
(Fig. 4D and Supplementary Fig. 7) between these two cell types.
Of interest, Amyloid β A4 protein (APP), fibronectin and heat
shock protein 90 were significantly upregulated in CAF CMed
(Fig. 4E), all of which have been implicated in NETosis in
different disease contexts41–44. Treatment of neutrophils with a
fibronectin inhibitor had no effect on the ability of CAF CMed to
induce NETs (Supplementary Fig. 8A), thus, we examined APP in
greater detail. Similar to studies implicating Amyloid β peptide
driven NETosis in Alzheimer’s45, app mRNA was detected in
pancreatic CAFs at higher levels than pancreatic stellate cells
(Supplementary Fig. 8B) and this was maintained at the protein
level with Amyloid β detected in CAF CMed (Fig. 4F). Inhibition
of β-secretases, which regulate secretion of Amyloid β (BACE
1–2), by pancreatic CAFs in turn reduced Amyloid β in the media
to levels comparable with basal controls (Fig. 4F). Upon
determining that recombinant Amyloid β but not Amyloid α
was able to induce NETosis in a dose-dependent manner
(Supplementary Fig. 8C) we next assessed whether Amyloid β
was present in NET-rich tumors. In pancreatic tumors, two
distinct patterns of APP distribution were observed with regions
displaying either diffuse or punctate staining that co-localized
with CAFs and tumor cells (Fig. 4G) consistent with Amyloid β
aggregates observed in other diseases. These data suggest that
CAFs are a source of Amyloid β in the tumor, a key driver of
NETosis.
To confirm that it was Amyloid β within CAF CMed that was
responsible for the observed effects on neutrophils in tumors, we
inhibited BACE 1–2 in CAFs to prevent Amyloid β production
(as shown in Fig. 4F). BACE inhibition in pancreatic and lung
CAFs abolished the ability of the CMed to induce NETs in vitro
(Fig. 4H) supporting the hypothesis that Amyloid β production
by CAFs underlies their capacity to induce t-NETs. A trend
towards reduced neutrophil death was also observed in the
absence of Amyloid β (Supplementary Fig. 9A) indicating that
ROS-mediated, suicidal NETosis in the tumor context is
potentially driven by a single CAF-derived factor.
To further support our observations, I/V infusion of CAF
CMed derived from CAFs pre-treated with BACE inhibitor to
suppress Amyloid β production, abolished the systemic effects
measured with CAF CMed (Fig. 4I and Supplementary Fig. 9B),
whilst the effect of CAF CMed in vivo was recapitulated by
infusion of recombinant Amyloid β alone (Fig. 4I). We next
examined the effects of BACE inhibition in vivo, in skin tumor-
bearing mice (Fig. 4J) using the same treatment regime as Cl-
amidine and GSK484. As with inhibitors of NETosis, disruption
of Amyloid β secretion prevented further increases in tumor
volume compared with vehicle controls (Fig. 4J), implying that
CAF-driven Amyloid β-mediated NETosis supports tumor
development in vivo, and that perturbation of either the NET
driver or NET process is sufficient to prevent growth. This was
confirmed using the B16.F10 melanoma model which is both
neutrophil and NET poor35. Treatment with CAF CMed or
recombinant Amyloid β increased tumor growth (Fig. 4K),
potentially coinciding with enhanced infiltration of NETting
neutrophils (Supplementary Fig. 9D).
We then considered how CAF-derived Amyloid β may exert its
effects on neutrophils. In light of reports that CD11b may act as a
receptor for Amyloid β46, we blocked CD11b during CAF CMed
treatment and found that it completely abolished NETosis (Fig. 4L
and Supplementary Fig. 9C) without affecting other functions
such as phagocytosis (data not shown). In contrast, TLR2
neutralization on CAF CMed treated neutrophils had no effect
on their capacity to NET (Fig. 4M and Supplementary Fig. 9C).
Thus, CD11b on the surface of neutrophils may indeed function
as a receptor, with its blockage desensitizing cells to the effects of
Amyloid β present in CAF CMed.
Fig. 3 Inhibiting t-NETosis stops tumor growth in vivo. A Schematic of GSK484 treatment regime of skin tumor-bearing mice. B Relative volume of skin
tumors on mice treated with vehicle or GSK484 over 8d. C Flow cytometric analysis of the percentage immune cells (CD45+), myeloid cells (CD11b+),
macrophages (F4/80+) and neutrophils (Ly6G+) in the tumor. D Representative confocal images showing neutrophils (myeloperoxidase (MPO) in green)
within the tumor in control or treated animals (zoomed inset). Nuclei counterstained with DAPI (white). E The levels of clotting factors (fibrinogen and von
Willebrand factor; vWF) in the plasma of skin tumor-bearing mice treated with vehicle or GSK484. F Quantification of CD11b, CD18 and CD62L expression
on wild-type bone marrow-derived neutrophils after 3-h treatment with pancreatic CAF CMed, with and without Cl-amidine, in vitro by flow cytometry.
G The phagocytic capacity of wild-type bone marrow-derived neutrophils after 3-h pancreatic CAF CMed, with and without Cl-amidine, treatment based on
uptake of fluorescent 1 µm beads in vitro assessed by flow cytometry. H Quantification of ROS production by wild-type bone marrow-derived neutrophils
after 3-h treatment with pancreatic CAF CMed, with and without Cl-amidine, in vitro based on the levels of DCFDA by flow cytometry. I Quantification of
neutrophil degranulation based on CD35 and CD63 expression by flow cytometry after 3-h pancreatic CAF CMed, with and without Cl-amidine for 3 h.
J Representative plot illustrating tumor cell growth following treatment with neutrophil-derived media with and without PAD4i treatment. Bar graphs are
mean ± SEM; *p < 0.05, **p < 0.01 and ***p < 0.001 using B a Mann–Whitney test comparing vehicle and GSK484 at each time point, E a Mann–Whitney
test and F–I a one-way ANOVA with a Tukey post hoc test. Box and whiskers graph-line: median, box: upper and lower quartiles, whiskers: maxima and
minima. Assays were performed on male and female, 8–24-wk-old mice B n= 8 (Vehicle) and n= 7 (GSK484), C n= 7 (Vehicle) and n= 4 (GSK484),
D Representative images of n-4 (Vehicle) and n= 6 (GSK484) tumors, E n= 6 (Vehicle) and n= 4 (GSK484) for Fibrinogen and n= 7 (Vehicle) and n= 4
for vWF, F n= 3 (in triplicate or single) G n= 3 (in triplicate) H n= 3 (in triplicate) I n= 3 (in triplicate) and J Representative of n= 2 (in duplicate)
independent experiments. Scale bars are 100 µm.
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NETs reciprocally activate CAFs. Whilst we observed that t-
NETosis was entirely soluble mediator driven (Fig. 4A), the fact
that NETs observed in the primary tumor site were often
restricted to CAF dense regions (Fig. 1A) led us to ask if t-NETs
had reciprocal, pro-tumor effects on the phenotype and function
of CAFs in their proximity. Treatment of CAFs with NETs
supported an enhanced proliferation of CAFs (Fig. 5A), and
induced features of activation in vitro (Fig. 5B–E).
We observed an increase in contraction of CAFs based on the
appearance of large gaps between cells after treatment with NETs
derived from CAF CMed treated neutrophils compared to FBs
treated with NETs, which remained as a monolayer (Fig. 5B). To
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assess the contractile properties of the CAFs after treatment with
t-NETs, we performed contraction assays. t-NET treated CAFs
contracted collagen gels to a greater extent than CAFs treated
with unstimulated NETs (Fig. 5C). This coincided with an
increased expression of αSMA and Col1a2 at the RNA level
(Fig. 5D) and collagen I imaging indicated these changes may be
reflected at the protein level (Fig. 5E). Examination of skin
tumors treated with either PAD4 or BACE inhibitors revealed a
reduced cellularity per unit tumor volume when compared with
vehicle-treated tumors (Fig. 5F, G). Moreover, consistent with
earlier observations that NET inhibition promoted degranulation
and impaired tumor cell growth (Fig. 3I, J), a similar effect was
mirrored in CAFs (Fig. 5H). Fibrotic structures with more mature
collagen made up the remaining tumor mass (Fig. 5G lower
panel). Collectively, these data suggest that neutrophils skewed to
undergo NETosis likely localise to CAF-rich regions of a tumor
where they form t-NETs in response to Amyloid β, promoting
CAF expansion, contractility and deposition of matrix compo-
nents supportive of tumor growth.
Conservation of Amyloid β-NET axis in human disease. Having
observed a significant pro-tumor communication between CAFs
and neutrophils in multiple murine models, we sought to deter-
mine the clinical significance of these findings by examining
human tumors. t-NETs were observed in human pancreatic
tumors (Fig. 6A), melanoma and melanoma metastases (Fig. 6B
and Supplementary Fig. 10A), and when detected, both NETs and
neutrophils were found juxtaposed to CAFs mirroring murine
tumors. We next examined publicly available datasets for APP
and β-secretase expression. Significantly, both pancreatic adeno-
carcinoma and cutaneous melanoma expressed elevated levels of
APP and BACE2 compared to matched normal tissue (Fig. 6C,
D). When detected, elevated levels of Amyloid β could be mea-
sured circulating in the blood of patients with advanced mela-
noma compared with heathy controls (Supplementary Fig. 10B).
Moreover, expression of both app and bace2 strongly correlated
with stromal markers pdpn, acta2, col1a2, cd34 typically used to
identify CAFs, but not the lymphatic marker lyve-1 (Fig. 6E)
inferring that correlations were specific to CAFs and not other
components of the tumor stroma. These data recapitulate murine
tumors, supporting CAFs as a source of Amyloid β in human
pancreatic cancer and melanoma. The high expression of bace2,
the rate-limiting step in Amyloid β release, was correlated with
poorer patient prognosis in both tumor types (Fig. 6F) while high
expression of app did not correlate with patient outcome
(Fig. 6G). Collectively, these findings suggest that Amyloid β
secreted by CAFs is a critical driver of t-NET formation con-
served in human cancers associated with poor prognosis, and
importantly, has the potential to be detected in liquid biopsies.
Discussion
The stroma is critical to tumor development and progression and
it is evident that targeting stromal interactions offers many
opportunities for cancer treatments1. Here, we report the exis-
tence of a previously undescribed pro-tumor crosstalk between
non-immune and immune stromal components to support tumor
growth. We demonstrate that neutrophils recruited to the tumor
frequently localize to CAF-rich areas, where they are stimulated
to generate extracellular traps (NETs) supporting tumor growth.
This process, which we have termed tumor-induced NETosis (t-
NETosis), is driven by CAF-secreted Amyloid β both locally via
CD11b on neutrophils within the primary tumor and at the
systemic level within the bone marrow niche.
While neutrophil function has been extensively studied in the
context of inflammation and tissue damage47–49, there have been
fewer studies relating to their contribution to the primary
tumor32,50,51 and mediators responsible for driving their
release21,51. Contradictory studies have reported NET-derived
proteins acting to both promote tumor cell proliferation and
invasion52,53, as well as inhibit tumor growth through apoptosis
induction32,54. In advanced disease, NETs have been reported to
contribute to thrombus formation21, metastatic colonization22,23
and most recently the reactivation of dormant tumor cells29.
Previous studies point to a central role for G-CSF in recruiting
neutrophils and to date this is one of the few factors that has been
identified as a NET inducer21,35. This is particularly thought
provoking given that cancer patients that are at high risk of
becoming neutropenic receive G-CSF therapy in an attempt to
restart myelopoiesis after chemo- and radiotherapy55. Consistent
with previous studies we found that CAF-induced NETosis was
ROS and PAD4-dependent14, but in this case did not require G-
CSF.
With CAFs possessing such a potent effect on neutrophils via
mechanisms distinct from previously described for systemic
NETosis21, we then examined the contribution of NETs in
tumors. Inhibition of t-NETosis in mice with established tumors
had no impact on neutrophil infiltration, yet was sufficient to
abolish further growth. In these tumors, PAD4 inhibition
Fig. 4 Amyloid β is the driver of CAF-induced t-NETosis. A Quantification of the relative NET coverage of neutrophils that were added to lung CAFs
treated with or without FB CMed, CAF CMed or PMA for 3 h. B Quantification of the relative NET coverage of neutrophils treated with lung CAF CMed or
CAF CMed-derived microvesicles (MV) or CMed depleted of MV. C Quantification of the relative NET coverage of neutrophils treated with lung CAF
CMed or the metabolite or protein fractions of the CAF CMed. D Differentially secreted proteins in pancreatic FB and CAF CMed analyzed by mass
spectrometry. The relative intensity of each protein is indicated by the colored bar under the heatmap. E Spectral counts for NET-related factors secreted
by pancreatic FBs and CAFs. F Levels of Amyloid β in basal media and pancreatic CAF CMed generated in the presence or absence of an inhibitor of
amyloid-beta secretion (BACEi). G Confocal microscopy of amyloid precursor protein (APP) and Podoplanin (PDPN) expressed by CAFs in pancreatic
tumors. Insets depict diffuse vs. aggregated patterns of APP/Amyloid β distribution. H Quantification of the relative NET coverage of neutrophils treated
with pancreatic and lung CAF CMed generated with or without 24-h pre-treatment of the CAFs with a β-secretase 1 and 2 (BACE1-2) inhibitor. I
Quantification of the relative NET coverage of bone marrow neutrophils taken from wild-type mice intravenously infused with pancreatic CAF CMed taken
from cells treated with or without BACE1-2 inhibitor for 24 h or recombinant Amyloid β. J Schematic of BACEi treatment regime of skin tumor-bearing mice
and relative endpoint volume of skin tumors (calculated relative to the volume of each tumor at the start of treatment—indicated by dotted line on the
graph) on mice after treatment with vehicle or BACEi (Z-VLL-CHO). K Growth of orthotopically implanted B16.F10 tumor cells with vehicle, CAF CMed or
recombinant Amyloid β treatment. Quantification of the relative NET coverage after 3-h treatment with pancreatic CAF CMed with or without L CD11b or
M TLR2 blocking antibodies. Data are mean ± SEM; **p < 0.01 and ***p < 0.001 using (A and H) one-way ANOVA with a Dunnett post hoc test, B–C, I and
L–M one-way ANOVA with a Tukey post hoc test and J a Mann–Whitney test. Assays were performed on A n= 6 (Untreated and CAF CMed treated) n=
3 (PMA and FB CMed treated), B n= 7, C n= 5, (E) n= 3, F n= 3–6, G Representative images of n= 3 tumors, H n= 6 (in triplicate), I n= 7 (in duplicate
or triplicate), J n= 9 (Vehicle) and n= 3 (BACEi) male and female, 8–24-wk-old mice, K n= 6 8-wk-old female C57BL/6 mice and L–M n= 3 (in triplicate)
independent experiments. Scale bars are 50 µm.
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translated to a skewing of neutrophils to a cytotoxic, anti-tumor
N1-like phenotype19,56. Indeed, our data supported this
hypothesis, confirming enhanced expression of activation mar-
kers and degranulation after PAD4 inhibition.
We subsequently identified Amyloid β, a protein typically
associated with neurodegenerative disorders, as the critical CAF-
derived factor inducing t-NETs. Inhibition of Amyloid β or its
proposed cognate receptor, CD11b46, prevented CAF-mediated
NETosis and reduced growth of established tumors. Moreover,
the addition of soluble Amyloid β exacerbated tumor growth
further implicating NETosis as pathological response in the
cancer context. With the observed increase in expression of
CD11b on neutrophils after CAF CMed treatment, our data imply
that CAFs not only secrete the Amyloid β to drive NETosis, but
may also render the neutrophils more responsive to circulating
Amyloid β in tumor-bearing animals through increased expres-
sion of its receptor46. This is in line with reports that Amyloid β
can induce ICAM-1 expression by endothelial cells suggesting
that it may play additional roles in the high-affinity capture of
infiltrating neutrophils41,57.
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In Alzheimer’s disease, Amyloid-driven NETosis has been
associated with poor prognosis as a consequence of endothelial
and parenchymal damage, and neurotoxicity57–59. In this context,
aggregation of Amyloid β not only drives the cognitive symptoms
associated with Alzheimer’s, but its soluble form also acts as a
DAMP, contributing to the neuroinflammation which perpe-
tuates progression60,61. In cancer, we observed that Amyloid β
secreted by CAFs form microaggregates in the tumor to drive
NETosis in situ as well as disseminating into the blood where it
conditions circulating and bone marrow resident neutrophils.
This raises the possibility that microaggregates of CAF-derived
Amyloid β also act as a DAMP inducing aberrant NETosis to
support tumor progression.
We provide evidence that neutrophils in pancreatic, skin and
lung cancers exposed to CAF-derived cues exert pro-tumor effects
that operate on multiple levels. Suppression of t-NETs in tumor-
bearing mice by inhibition of PAD4, or release of Amyloid β by
BACE inhibition not only suppressed tumor growth but also
brought about a decrease in thrombus formation as quantified by
levels of clotting factors; vWF and fibrinogen. With previous
reports showing that NETs both contribute to thrombus forma-
tion, metastatic colonization and activation of dormant tumor
cells21–23,29,35 our findings that perturbation of either the driver
or consequence of NETosis is sufficient to prevent tumor growth
present the CAF-Amyloid-neutrophil axis as an attractive target.
While the therapeutic potential of PAD4 blockade has yet to be
clinically tested, it is possible that this approach may only provide
a narrow therapeutic window since the inhibitor acts when PAD4
is in a high calcium-binding state62, and may increase suscept-
ibility to infection where NETosis is a critical response for bac-
terial clearance. Thus, inhibiting Amyloid β, for which drugs
targeting BACE’s have already received FDA approval63, and
preventing neutrophils from receiving a NET stimulus may
represent a more effective platform. Importantly, this would block
pathological NETosis both at the primary tumor and systemically
without impacting other critical neutrophil functions.
With the growing body of evidence supporting a role for NETs in
advanced cancer—metastatic colonization and recurrence23,29,64,
and clinical data linking neutrophil infiltration with poor prognosis
in multiple cancer types65–69—our findings warrant further studies
to determine whether Amyloid β (circulating, or in the primary
tumor) can be used as a biomarker to stratify patients. Although, in
neuroinflammatory conditions such as Alzheimer’s disease, circu-
lating Amyloid β is not currently considered to be a biomarker
reflective of levels in the cerebrospinal fluid and central nervous
system70, we reported no significant difference in Amyloid β levels
in our small cohort of melanoma patients compared to healthy
volunteers. However, this would merit assessment in a much larger
cohort. A number of external factors may be responsible for the
observed variability; Circulating Amyloid β1–40 and β1–42 are pre-
dominantly bound to plasma proteins, and platelets or erythrocytes
which can mask detection70. Furthermore, differences in the hepatic
and renal clearance of Amyloid β may influence the levels mea-
sured70. Despite the difficulties in quantifying plasma Amyloid β
levels, recent studies have implicated plasma Amyloid β in cancer.
Higher levels of plasma Amyloid β were detected in hepatic cancer
patients than those with Alzheimer’s disease71, indicating that while
cerebrospinal fluid levels are predictive of Alzheimer’s, circulating
Amyloid β levels may be more reflective of cancer71. Furthermore, it
has been reported that breast and prostate tumor cells undergo
amyloidosis as a result of environmental stress leading to cancer cell
dormancy. This is particularly interesting in light of the recent study
which implicated NETosis as a driver of dormant cancer cell acti-
vation in lung cancer72. Indeed, amyloid accumulation in tumor
cells may force the cells into a dormant state but as a consequence
may also induce NETosis which could result in their activation and
in a negative feedback system, re-initiation of the tumor.
Amyloid β-induced NETosis potentially support tumor growth
through reciprocal effects on CAFs in close proximity. Here we
showed that t-NETs supported changes in morphology, pro-
liferation and activation status of CAFs leading to a more con-
tractile and matrix-producing phenotype. Activation, matrix
deposition and consequent matrix stiffening are all pro-tumor
traits exhibited by CAFs that are correlated with disease pro-
gression and promotion of tumor growth in many cancers1,4.
Without directly affecting tumor cell proliferation, alterations to
CAF phenotype and functional traits have the potential to impact
multiple components of the tumor microenvironment via several
mechanisms, including the direct support of cancer cell invasion,
growth factor release, cytokine production and bioavailability, as
well as, modulating functional status, physical exclusion, and
altered trafficking of immune cells. Similar phenomena have also
been reported in fibrosis where NETosis was found to drive
activation, differentiation and the fibrotic response of human
lung fibroblasts18. Therefore, the direct action of Amyloid β on
tumor cells previously reported72 is distinct to the indirect effects
it has on the tumor stroma through the induction of NETosis,
further supporting a potential rationale for using BACE inhibitors
to treat cancer.
In summary, we have demonstrated the existence of a novel
mechanism by which CAFs stimulate t-NETosis at local and
systemic levels via production of Amyloid β. Targeting this pro-
cess with existing small molecule inhibitors stops tumor growth
and restores a pro-inflammatory neutrophil phenotype. This sets
the stage for further studies examining the potential of ther-
apeutically targeting NETs to treat cancer.
Fig. 5 t-NETs induce CAF activation. A Representative plot illustrating growth of CAFs in the presence of vehicle or micrococcal nuclease detached NETs.
B Phase contrast images and respective quantification of the percentage area of cell free space per field after treatment of pancreatic FBs or CAFs with
NETs derived from CAF CMed treated neutrophils for 24 h. (C) Quantification of the size of collagen gels 24, 48, and 72 h after seeding pancreatic CAFs
treated with or without NETs derived from CAF CMed treated neutrophils for 24 h. D Expression of Acta2 and Col1a2 at the gene level in pancreatic
CAFs treated with or without NETs derived from CAF CMed treated neutrophils for 24 h. E Confocal microscopy of Collagen1 and phalloidin on pancreatic
CAFs treated with or without NETs derived from unstimulated neutrophils or CAF CMed treated neutrophils for 24 h. F Cellularity of melanoma after
treatment with GSK484, Cl-amidine, BACEi or vehicle expressed as cells per unit volume. G Representative confocal image of nuclei and collagen after
treatment with GSK484, Cl-amidine, or vehicle. Tissues stained with Herovici stain to demark new collagen (blue) vs. mature collagen (pink). H
Representative plot illustrating growth of CAFs following treatment with CAF CMed or CAF CMed and PAD4i-treated neutrophil-derived media. Bar graphs
are mean ± SEM; *p < 0.05 and ***p < 0.001 using B–D a paired t-test and F a Mann–Whitney test. Box and whiskers graph-line: median, box: upper and
lower quartiles, whiskers: maxima and minima. Assays were performed on (A and H) Representative of n= 2 (in duplicate), B n= 3 (in triplicate), C n= 3
(in duplicate or quadruple), D n= 4 (in duplicate), E Representative images of n= 3 samples, F n= 5–10 male and female, 8–24-wk-old mice, and
G Representative images of n= 5 (Vehicle) and n= 5 (GSK484 and Cl-amidine) independent experiments. Scale bars are 50 µm (B and E), 500 µm
(G upper panel) and 100 µm (G upper panel).
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Methods
Mice. The care and use of all mice in this study were in accordance with the UK
Animals in Science Regulation Unit’s Code of Practice for the Housing and Care of
Animals Bred, Supplied or Used for Scientific Purposes, the Animals (Scientific
Procedures) Act 1986 Amendment Regulations 2012. All procedures were performed
under a UK Home Office Project license (PPL 80/2574 or PPL P88378353), which
were reviewed and approved by the Medical research Council Laboratory of Mole-
cular Biology (PPL 80/2574 or PPL P8837835) Animal Welfare and Ethical Review
Bodies (AWERB). Mice were kept in specific pathogen-free (SPF) barrier conditions
and once recruited to studies, remained socially housed in individually ventilated
cages, at ambient temperature and with cage enrichment. For spontaneous genetic
mouse tumors, Tyr::CreER; BrafCA; Ptenlox/lox (melanoma; stock number 013590, The
Jackson Laboratory), the LSL-KrasG12D/+;LSLTp53R172H/+;Pdx-1-Cre (pancreatic
tumor, provided by Tobias Janowitz), and inducible LSLKrasG12D/+;p53LSL-
R270H/ER (lung tumor, as described in ref. 73) model systems were tested. Orthotopic
syngeneic tumors using B16.F10 melanoma were performed in ~8-week-old female
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C57BL/6 mice bred in house. Syngeneic subcutaneous pancreatic tumors (cells pro-
vided by Professor David Tuveson, CSHL) were generated in ~8-week-old female
C57BL/6 mice or PAD4–/– (provided by Markus Hoffmann, University of Erlan-
gen and originally derived from Kerri Mowen, Scripps Institute) and littermate
control mice (on a C57BL/6 genetic background).
PAD4 inhibition in vivo. Male and female spontaneous skin (8–24-wk old) or
pancreatic (8–32-wk old) tumor-bearing mice, were treated with PAD4 inhibitors;
3.5 mM Cl-amidine (EMD Millipore), 20 mg/kg GSK484 (Cayman Chemicals) or a
vehicle control (DMSO). Where possible, technicians performing the experiment
were blinded to drug treatments. Mice were recruited when tumors reached
between 3–6 mm in diameter and then received I/P doses of PAD4 inhibitor or
vehicle control every day for 7d or until tumors reached their size limit (12 mm
max. diameter) and mice were then euthanized by exposure to CO2 followed by
cervical dislocation or exsanguination as a confirmation of death. The size of
genetic pancreatic tumors was monitored by high-resolution ultrasound, as pre-
viously described2. For skin and subcutaneous pancreatic tumors, the volume was
recorded daily using the formula (π/6)(shortest length*longest length)2. All mice in
the study were monitored daily, and tumor size measured non-invasively with
digital calipers. After treatment, the cellularity of the tumors was determined by
flow cytometric analysis of the number of cells present in the tumor after digestion
of the tissue. The number of cells was then normalized to tumor size. Plasma was
isolated from skin and pancreatic tumor-bearing mice by collecting the blood from
cardiac puncture and centrifuging at 800 × g for 10 min. Plasma was then snap
frozen for measurements of analytes at a later stage.
BACE inhibition in vivo. Spontaneous skin tumor-bearing (male and female,
8–24-wk old) mice were treated with 5 mg/kg BACE inhibitor (Z-VLL-CHO,
Abcam) or vehicle control. Mice were recruited when tumors reached between
3–6 mm in diameter and then received I/P doses of BACE inhibitor for 7d or until
tumors reached their size limit (12 mm max. diameter) and mice were then
euthanized by exposure to CO2 followed by cervical dislocation or exsanguination
as a confirmation of death. Mice were monitored and measured daily with digital
calipers, and tumor volume was calculated daily using the formula (π/6) (shortest
length*longest length)2. After treatment, the cellularity of the tumors was deter-
mined by flow cytometric analysis of the number of cells present in the tumor after
digestion of the tissue. The number of cells was then normalized to tumor size.
Amyloid β and CAF CMed treatment of tumors. 2.5 × 105 B16.F10 melanoma
cells were inoculated subcutaneously into the shoulder region of 8-week-old female
C57BL/6 mice. Where possible, technicians performing the experiment were
blinded to drug treatments; At day 5, day 7, and day 9, mice received I/P infusion
of either vehicle, CAF CMed or recombinant Amyloid β. Mice were monitored and
measured daily with digital calipers, and tumor volume was calculated using the
formula (π/6)(shortest length*longest length)2. After 11 days or when the tumors
reached the size limit, the mice were euthanized. The immune landscape and CAF
composition of the tumors was analysed by flow cytometry.
CAF CMed treatment in vivo. For investigations of CAF factors in vivo in the
absence of tumors, CAF or FB CMed diluted 1:1 in complete culture media or
250 μg/ml recombinant amyloid β was I/V infused into C57BL/6 mice and the bone
marrow was harvested 24 h later.
Cell isolation and culture. CAFs were isolated from skin, lung (58) and pancreatic
tumor-bearing mice by mechanical separation of the tumor followed by digestion
with an enzymatic cocktail consisting of 1 mg/ml collagenase A and collagenase D
and 0.4 mg/ml DNase I (all from Roche) in PBS at 37 °C for 2–3 h with rotation at
600 rpm in a thermomixer compact (Eppendorf). 10 mM EDTA was then added to
stop the enzymatic reaction. Normal FBs were isolated from matched tissues of
wild-type mice using the same method. CAFs and normal FBs were maintained in
RPMI (Sigma- Aldrich) with 1.5 g/L NaHCO3, 10% fetal bovine serum (Life
Technologies), 1% penicillin-streptomycin (Sigma-Aldrich), 10 mM HEPES
(Gibco), 15 μM β-mercaptoethanol (Sigma-Aldrich).
CMed generation and fractionation. CMed from FB and CAFs was generated by
culturing the cells until they reached 40–50% confluence and then changing the
media to complete endothelial cell culture medium (Generon). The media was then
harvested after 24 h and filtered through 0.2 μm cell strainers before freezing. In
some experiments, pancreatic or lung CAFs were treated with an inhibitor to beta-
site Amyloid precursor protein cleaving enzyme 1 and 2 (BACE) (0.7 μM; Abcam)
for the duration of CAF CMed generation to inhibit Amyloid β production by
the cells.
CAF CMed was also separated into the metabolite (<3 kDa) and protein (more
than 3 kDa) fractions using 3 kDa centrifugal filters (Merck Millipore) according to
the manufacturer’s instructions. To isolate extracellular vesicles (MVs), CAF CMed
was ultracentrifuged at 100,000 g for 90 min. MV depleted CMed was collected and
the isolated MVs were resuspended in complete culture media.
Neutrophil isolation. Wild-type male and female C57BL/6 mice were euthanized
by cervical dislocation. Femurs and tibias were removed and bone marrow aspirate
was collected. Neutrophils were isolated using a two-step Histopaque density
gradient as previously described74. Purified neutrophils were washed in PBS. To
test the NETting capability of neutrophils from tumor-bearing mice, bone marrow
from mice bearing skin, lung and pancreatic tumors of varying size were isolated.
NETosis assay. Bone marrow-derived neutrophils were counted and seeded onto
poly-D-lysine coated plates at a density of 1 × 105 cells per condition in serum-free
media. The media was changed to complete endothelial cell culture medium
(Generon). To study NETosis, neutrophils were either treated with 1 μg/ml PMA,
CMed derived from FB or CAFs mixed 1:1 with complete culture media. Neu-
trophils were treated for 3 h at 37 °C and 5% CO2 and then stained with 20uM
SYTOX™ Green Nucleic Acid Stain for 10 min (Thermofisher Scientific). Images
and videos were taken using a Zeiss Axio Observer.Z1 coupled with incubation
chamber (ZEISS). Five images were taken per well and each condition was per-
formed in duplicate or triplicate.
To test the effects of ROS on NETosis, neutrophils were treated with anti-
oxidants; 10 mM n-acetyl cysteine (NAC), 20 μM DPI, 2 mM Trolox and 2 mM
Vitamin C for 30 min prior to inducing NETosis and for the duration of the NET
assay. Alternatively, neutrophils were treated with 0.03 μg/ml α-G-CSF (R&D
Systems) or 50 μM Chloroquine (Sigma-Aldrich) for the duration of the NET
assay. In some experiments, neutrophils were treated with 1.5 mg/ml Cl-amidine,
an inhibitor of the PAD4, 10 μg/ml anti-CD11b or anti-TLR2 (Biolegend) or 1 μg/
ml fibronectin inhibitor (Santa-Cruz Biotechnology) for the duration of culture.
The area of NET coverage was quantified using ZEN Lite (ZEISS) and ImageJ (Fiji)
software by drawing around every NET within a field. Dead cells (positive for
SYTOX green) were also counted per field.
NET isolation and quantification. After NET generation, neutrophils were treated
with 1U/ml micrococcal nuclease (Sigma-Aldrich) for 10 min (found to be the
optimum time for detaching NETs from neutrophils without digesting the NETting
DNA) at 37 °C and 5% CO2. The enzyme was inactivated with 0.5 mM EDTA.
Gel contraction assays. Pancreatic CAFs were treated for 24 h with ~10 ng/ml
NETting DNA (taken from 1 × 105 neutrophils stimulated with CAF CMed or
PMA) or from untreated neutrophils. CAFs were trypsinized and then seeded
into 2 mg/ml collagen gels (Rat tail collagen, BD Biosciences) at a density of 1 ×
105 cells/gel in 24-well plates. Gels were left to polymerise for 20 min at 37 °C
before adding full media. The gel was detached from the culture dish using a
pipette tip. The gels were imaged at 24, 48, and 72 h after generation. The area of
the gel was then measured using ImageJ software. The relative gel area was then
calculated by comparing it to gels containing untreated CAFs.
Flow cytometry. Tumors were minced using a razor and digested with 1 mg/ml
collagenase A and collagenase D and 0.4 mg/ml DNase I in PBS at 37 °C for 2 h
with rotation at 600 rpm in a thermomixer compact (Eppendorf). 10 mM EDTA
was then added to stop the enzymatic reaction. The cell suspension was passed
through a 70 μm filter and stained with live/dead fixable violet stain (Thermofisher
Scientific). Cells were subsequently stained with the following fluorescently con-
jugated antibodies; CD45 (30-F11), Ly6G (1A8), F4/80 (BM8), CD11b (M/170),
Fig. 6 Conservation of t-NETs in human disease. A Representative confocal images of NETting neutrophils and CAFs in human pancreatic tumor biopsies
(MPO, green; CitH3, red; podoplanin, blue; DAPI, white). B Representative confocal images of NETting neutrophils and CAFs in human melanoma primary
tumor and metastasis samples (MPO, green; CitH3, red; podoplanin, blue; DAPI, white). C Median expression of app in human pancreatic adenocarcinoma
and cutaneous melanoma compared to normal tissue from healthy donors and D Median expression of bace2 in human pancreatic adenocarcinoma and
cutaneous melanoma compared to normal tissue from healthy donors (GTEx and TCGA datasets). E Correlation of app and bace2 with a lymphatic marker
(lyve1) and CAF markers (pdpn, acta2, col1a2 and cd34). Kaplin–Meier curves showing overall survival of pancreatic adenocarcinoma and cutaneous
melanoma patients correlated with high and low expression of (F) bace2 or (G) app. (A) Representative images of at least n= 3 tumors. Scale bars
are 50 µm.
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CD11c (N418), Thy1 (30-H12), Podoplanin (8.1.1.), PDGFRα (APA5; all from
Biolegend) and CD31 (390; eBioscience) at 1:300 dilution. Flow cytometry was
performed on LSR Fortessa (BD Biosciences) analyzers. Unstained and single-
stained compensation beads (Invitrogen) were run alongside to serve as controls.
Offline analysis was carried out on FlowJo (Treestar). For in vivo PAD4 inhibitor
studies, tumors were separated for flow cytometric and immunofluorescent ana-
lysis. Some GSK484 treated tumors were too small for analysis and were therefore
excluded (only tumor volumes were recorded).
In vitro treatment of skin tumor cells with PAD4 inhibitors. Tumor cells were
isolated from skin tumors by digestion with 4 mg/ml Collagenase A for 1 h at 37 °C.
The cells were then strained through a filter and seeded onto a culture dish in
DMEM supplemented with 5% FBS and 1% penicillin/streptomycin. The cells were
cultivated for 3–4d and then seeded onto 24-well plates at a density of 3 × 104 cells/
well. The cells were either treated with DMSO (vehicle control), 100 µM Cl-
amidine or 10 µM GSK484 for 48 h. Images were taken at 0, 24, and 48 h after
treatment.
In vitro neutrophil staining. Bone marrow neutrophils were isolated as described
above and treated with lung FB or CAF CMed for 30 min. Neutrophils were then
treated with 10 μM 2′,7′-Dichlorodihydrofluorescein diacetate (DCFDA; Sigma-
Aldrich) or 2 × 108 yellow/green 1 μm fluoresbrite beads (Polysciences Inc.) for 20
min. Alternatively, neutrophils were treated with CMed and stained with anti-
bodies for CD11b (M/170), CD18 (M18/2) and CD62L (MEL-14; all from Biole-
gend). In some experiments, neutrophils were treated with CMed and stained with
Annexin V (BD Pharmingen) and 7-AAD (Thermofisher Scientific) for 30 min. For
all experiments, the cells were washed and then immediately analyzed by flow
cytometry.
PAD4 inhibitor treatment on neutrophil function in vitro. Murine bone marrow
neutrophils were seeded at 1 × 105 cells per condition in complete endothelial cell
culture medium mixed 1:1 with pancreatic CAF CMed. Neutrophils were treated
with or without 1.5 mg/ml Cl-amidine for 3 h. Neutrophil activation was then
assessed by measuring expression of CD11b, CD18, and CD62L. ROS production
was assessed by measuring DCFDA by flow cytometry (as above). The phagocytic
activity of the neutrophils was assessed by measuring fluorescent bead uptake by
flow cytometry. Neutrophil degranulation was determined by surface expression of
CD35 and CD63.
Characterization of CAFs and FB. Isolated CAFs and FB were stained for typical
markers; Podoplanin, PDGFRα and Thy1 (as described above) and markers to
exclude immune cells (CD45), endothelial cells (CD31) and epithelial cells
(EpCAM clone G8.8; all from Biolegend).
Gene expression analysis. Pancreatic CAFs were treated with ~10 ng/ml NETting
DNA (from CAF CMed or PMA stimulated neutrophils) for 24 h. RNA was iso-
lated using the RNeasy Mini Kit (Qiagen, Crawley, UK), converted to cDNA and
analyzed by qPCR using Universal PCR mastermix (Life Technologies) according
to manufacturer’s instructions. Primers were bought as Assay on Demand kits
from Applied Biosystems. qRT-PCR was performed using TaqMan assays (Col1a2
Mm00483888_m1, Acta2 Mm00725412_s1 and Gapdh Mm99999915_g1) and a
StepOne Real-Time PCR System (both Life Technologies). Levels of each gene were
expressed as 2−ΔCT (relative to Gapdh).
Analysis of Amyloid-related genes. Expression of app and bace2 and correla-
tions with CAF and lymphatic markers in human pancreatic adenocarcinoma
and skin cutaneous melanoma compared to healthy tissue were analyzed
using GEPIA RNA-sequencing expression data taken from the publicly available
TCGA and GTEx projects [http://gepia.cancer-pku.cn]75. For mouse pancreatic
tumor samples, publicly available data were analyzed (GEO accession number
GSE42605).
Immunofluorescence and tissue stains. Tumors were snap frozen in OCT
medium (TissueTek). 5–7 µm sections were fixed in ice-cold acetone/methanol for
5 min. For formalin-fixed paraffin-embedded murine lung tumors (provided by
Daniel Munos-Espin, University of Cambridge), sections were first dewaxed in
xylene and rehydrated in graded alcohols then subjected to antigen retrieval in
Tris-EDTA pH9. Samples were blocked in 10% donkey serum in PBS and incu-
bated with primary antibodies overnight at 4 °C. Primary antibodies as follows:
Rabbit anti-citrullinated histone H3 R17+ R2+ R8 (ab5103, 1:500 dilution,
Abcam), goat anti-myeloperoxidase (AF3667, 1:1000 dilution, RnD Systems),
hamster anti-podoplanin (clone 8.1.1, 127402, 1:100 dilution, BioLegend), Alexa
488 conjugated mouse anti-APP (clone 22C11, MAB348A4, 1:100 dilution, Merck-
Millipore), mouse anti-αSMA (clone 1A4, MAB1420, 1:100 dilution, RnD Sys-
tems). Slides were washed, incubated with appropriate secondary antibodies and
counterstained with DAPI. Sections were mounted in Slowfade Gold (Invitrogen).
Images were acquired on a Leica SP5 confocal microscope. For visualization
of collagen, frozen 10 μm sections of murine skin tumors were stained with
Hematoxylin (Sigma) for 4 min then washed for 10 min under running tap water.
Slides were stained with Herovici staining solution (prepared as described in ref. 76)
for 2 min. The sections were then rinsed in 1% acetic acid and dehydrated by
placing slides in 100% ethanol until mounting. Slides were mounted in DPX
(Sigma) and then imaged under a light microscope.
Human samples. The research was conducted in full accordance with the
Guideline for Good Clinical Practice and the Declaration of Helsinki. All biological
materials used in this study and their subsequent evaluations were in accordance
with the informed consent agreements obtained from all subjects.
Human tissue and plasma samples from patients with advanced melanoma
(AJCC clinical stage III and IV) were kindly provided by the MELRESIST study
investigators (UK NRES committee North East – Newcastle & North Tyneside 2
Research Ethics committee review reference 11/NE/0312). Control plasma was
isolated from consenting healthy volunteers from the Cambridge Blood Centre.
Human tissue microarrays for pancreatic adenocarcinoma were obtained from a
commercial supplier (Biomax.US) and additional local ethical approval was
obtained for use of these TMAs in our study (HBREC 2019.16).
Immunofluorescence of human tissue. Formalin-fixed paraffin-embedded
human pancreatic TMA slides (Biomax), and melanoma samples were dewaxed in
xylene and rehydrated in graded alcohols prior to antigen retrieval in Tris-EDTA
pH9. Slides were blocked and incubated with primary antibodies as above at 4 °C
overnight. Samples were washed and incubated in fluorescently conjugated sec-
ondary antibodies before cell nuclei were counterstained with DAPI and sections
were mounted in Slowfade Gold and imaged on a Leica SP5 confocal microscope.
ELISA. Levels of murine Amyloid β42, (Fisher Scientific), vWF and fibrinogen
(both from Abcam) were measured in plasma collected from the skin and pan-
creatic tumor-bearing mice or in serum-free CMed from pancreatic CAFs as per
manufacturer’s instructions. Human platelet-poor plasma was obtained by cen-
trifuging whole blood from healthy donors at 2000 × g for 15 min. Samples were
immediately snap frozen until use. Archived melanoma patient plasma samples
(MELRESIST NRES: 11.NE.0312) and healthy controls were measured for levels of
Amyloid β42 (Abcam) as per manufacturers guidelines.
Mass spectrometry. FB and CAF CMed were generated without fetal bovine
serum for 24 h. The protein fractions were isolated and concentrated using 3 kDa
centrifugal filters (Merck Millipore). LC MS/MS was performed on the con-
centrated culture CMed and spectral analysis was performed. Data were analyzed
using Scaffold 4 software.
Measurement of the effects of NETs or NET CMed on tumor cell and
CAFs in vitro. 1 × 105 neutrophils were treated with CAF CMed diluted 1:1 in
complete EC media (Cell Biologics) with or without Cl-amidine and incubated for
3 h to generate NETs. The media was then harvested from the NETting or NET
inhibited neutrophils. PBS supplemented with 1U/ml micrococcal nuclease (Sigma-
Aldrich) was then added to the neutrophils for 10 min at 37 °C and 5% CO2 to
detach the NETs. The enzyme was inactivated with 0.5 mM EDTA. PBS containing
the NETs was then harvested for xCELLigence assays.
Pancreatic CAF or tumor cells were seeded onto 16 well E-plates (ACEA
Biologics) at a density of 5 × 103 cells/well. Cells were allowed to adhere for 1 h. The
media was then replaced with the NETting or NET inhibited neutrophil CMed.
Plates were placed into an xCELLigence RTCA MP Real-Time Cell Analyzer
(ACEA Biologics). Recordings of the impedance, correlating to cell proliferation,
were then taken over a 48 h period. The background was then subtracted from the
appropriate wells.
Statistical analysis. Data are expressed as mean ± SEM, where a different neu-
trophil isolate and batch of CMed was used for each experiment. Multi-variant data
were analyzed using analysis of variance (ANOVA), followed by Dunnett or Tukey
post-hoc tests. Mann–Whitney or t-test was used to compare individual treatment
conditions. p < 0.05 was considered statistically significant. For mass spectrometry,
differences in protein expression in FB and CAF CMed was considered significant
when the spectral count was p < 0.01. Data were analyzed using Graphpad Prism 7
and 8 Software packages.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Publicly available data were obtained from TCGA and the GTEx projects and the GEO
repository (accession number GSE42605). The raw numbers for study data are available
in the Source Data file wherever possible. Source data are provided with this paper.
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